PLx Pharma Winddown Corp.
PLXPQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 4.54M | 10.77M | 10.29M | 8.21M | 6.62M |
| Total Other Revenue | -- | -- | -- | -- | -400.00 |
| Total Revenue | 4.54M | 10.77M | 10.29M | 8.21M | 6.62M |
| Cost of Revenue | 4.34M | 6.79M | 5.97M | 4.81M | 3.91M |
| Gross Profit | 202.60K | 3.98M | 4.32M | 3.40M | 2.70M |
| SG&A Expenses | 62.11M | 63.98M | 55.83M | 40.01M | 21.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.97M | 74.22M | 65.68M | 49.00M | 30.25M |
| Operating Income | -64.42M | -63.45M | -55.39M | -40.79M | -23.63M |
| Income Before Tax | -27.58M | -40.72M | -45.37M | -46.12M | -57.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.58 | -40.72 | -45.37 | -46.12 | -57.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.58M | -40.72M | -45.37M | -46.12M | -57.67M |
| EBIT | -64.42M | -63.45M | -55.39M | -40.79M | -23.63M |
| EBITDA | -64.30M | -63.33M | -55.27M | -40.67M | -23.52M |
| EPS Basic | -0.99 | -1.49 | -1.86 | -2.19 | -3.19 |
| Normalized Basic EPS | -0.62 | -0.93 | -1.10 | -1.30 | -1.89 |
| EPS Diluted | -0.99 | -1.49 | -1.86 | -2.19 | -3.20 |
| Normalized Diluted EPS | -0.62 | -0.93 | -1.10 | -1.30 | -1.89 |
| Average Basic Shares Outstanding | 111.37M | 109.68M | 105.62M | 94.44M | 76.63M |
| Average Diluted Shares Outstanding | 111.37M | 109.68M | 105.62M | 94.44M | 76.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |